RIPK1 and malignant colon neoplasm: Nec-1 (Necrostatin-1), a type II inhibitor targeting the RIPK1 allosteric pocket, significantly reduces tumour burden (volume and number) in murine colon cancer models by inhibiting RIPK1 kinase activity and suppressing the JNK/c-Jun pathway.103